Cancer patients nowadays can choose a wide variety of cancer therapies based on new anti-cancer drugs and state-of-the art operational technology. Also, cancer has been recognized as curable diseases with increased cancer survivors. On the other hand, cancer survivors who have various problems during and after treatment of cancer therapy are increasing. Recently, as an increase in the number of cancer survivors, emphasis has been placed on the importance of development of survivors' QOL such as cardiovascular disorders occurred in cancer survivors. Indeed, certain anticancer drugs and molecular targeted therapies induce cardiotoxicity, which limit the widespread implementation of cancer treatment and significant decrease of QOL in cancer patients. In addition, cardiac dysfunction induced by cancer cachexia has also been reported. In view of these backgrounds, it is necessary to clarify the dynamics of cardiovascular system of cancer survivors and patients with cancer cachexia, to prevent cardiac dysfunction accompanying with cancer therapy and cachexia. Quite recently, interdisciplinary research area namely Cardio-oncology has been established to try to solve these issues. In the present study, we will present anticancer drug-induced cardiotoxicity and cardiac dysfunction occurring in cancer cachexia, and discuss our research approaches and data to understand such pathophysiology and possible prevention and therapies.

To: 要旨(抄録)